STOCK TITAN

Iovance Biotherp - IOVA STOCK NEWS

Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.

Iovance Biotherapeutics (IOVA) pioneers tumor-infiltrating lymphocyte (TIL) therapies for advanced cancers, leading the next generation of personalized immunotherapies. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical milestones, regulatory developments, and strategic initiatives.

Access timely announcements including FDA submissions, clinical trial data publications, manufacturing advancements, and partnership agreements. Our curated collection ensures you stay informed about IOVA developments impacting oncology treatment paradigms and biopharmaceutical innovation.

Key updates cover therapy approvals, research collaborations, financial results, and scientific presentations. All content is verified through primary sources to maintain accuracy and compliance with financial disclosure standards.

Bookmark this page for streamlined access to Iovance's latest progress in developing TIL-based therapies for melanoma, cervical cancer, and other solid tumors. Regularly updated to serve as your definitive resource for IOVA-related news analysis.

Rhea-AI Summary
Iovance Biotherapeutics grants inducement stock options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
none
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA): FDA Priority Review of Biologics License Application (BLA) for lifileucel in advanced melanoma is on track for potential approval and launch in 2023. The company reported second quarter and first half 2023 financial results, including corporate updates. The TIL program for post-Anti-PD-1 non-small cell lung cancer is advancing into registrational development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.44%
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics announced the oral and poster presentations of clinical and preclinical data for tumor infiltrating lymphocyte (TIL) therapies at the IASLC 2023 World Conference on Lung Cancer. The presentations will include data from the Phase 2 clinical trial of LN-145 in combination with pembrolizumab in anti-PD1-naïve advanced non-small cell lung cancer (NSCLC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences clinical trial
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) will report its second quarter 2023 financial results on August 8, 2023. The company focuses on developing polyclonal tumor infiltrating lymphocyte therapies for cancer patients. A conference call and live webcast will be held at 4:30 p.m. ET. Registration is required to participate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
conferences earnings
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announced the approval of the grant of inducement stock options to 8 new non-executive employees. The options cover an aggregate of 71,800 shares of Iovance's common stock and have an exercise price of $7.62. The options vest over a three-year period, with one-third of the shares vesting on the first anniversary of the employee's start date and the remaining shares vesting in eight quarterly installments over the next two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
none
-
Rhea-AI Summary
Iovance Biotherapeutics has closed an underwritten public offering of 23 million shares of its common stock at a price of $7.50 per share, raising $172.5 million. The company plans to use the proceeds for various purposes, including preparing for the commercial launch of lifileucel and supporting ongoing clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announces the pricing of an underwritten public offering of its common stock at $7.50 per share, with expected gross proceeds of approximately $150 million. The company intends to use the proceeds for various purposes including the commercial launch of lifileucel and the expansion of TIL and immune checkpoint inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.78%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.78%
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics receives positive FDA feedback for IOV-LUN-202 trial design in post-anti-PD-1 NSCLC. Preliminary data shows a 26.1% objective response rate with a disease control rate of 82.6%. Enrollment of approximately 120 patients expected to be complete by H2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.41%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences
Iovance Biotherp

Nasdaq:IOVA

IOVA Rankings

IOVA Stock Data

1.00B
279.26M
0.62%
84.02%
18.17%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN CARLOS